---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-25-000521"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:40:53.304157+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Nasdaq delisting Virpax; directors and CFO resign effective immediately

## Summary
- Nasdaq Hearings Panel determined to delist Virpax due to failure to meet minimum stockholders' equity under Rule 5550(b)(1).
- Trading suspended at open on April 4, 2025; Company not appealing.
- Three directors (Esha Randhawa, Charn Deol, Judy Su) resigned April 2, 2025.
- CFO Usama Chaudhry resigned same day, effective immediately; no disagreements cited.

## SEC filing metadata
- accession: 0001731122-25-000521
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000173112225000521/0001731122-25-000521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000173112225000521/e6489_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-25-000521
- JSON: https://secwatch.observer/filing/0001731122-25-000521.json
- Plain text: https://secwatch.observer/filing/0001731122-25-000521.txt

## Key facts
- Listing & Compliance Notices
  Virpax Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: April 2, 2025, Virpax Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of the Company’s failure to regain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). Trading in the Company’s common stock on Nasdaq will be suspended effective at the open of business on Friday, April 4, 2025. Nasdaq will complete the delisting by filing a Form 25 Notificati
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112225000521/0001731122-25-000521-index.htm
- Executive change
  Judy Su resigned as member of the Board of Directors at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: member of the Board of Directors
  source text: On April 2, 2025, Esha Randhawa, Charn Deol, and Judy Su each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112225000521/0001731122-25-000521-index.htm
- Executive change
  Charn Deol resigned as member of the Board of Directors at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: member of the Board of Directors
  source text: On April 2, 2025, Esha Randhawa, Charn Deol, and Judy Su each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112225000521/0001731122-25-000521-index.htm
- Executive change
  Usama Chaudhry resigned as Chief Financial Officer at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On the same date, Usama Chaudhry resigned from his position as Chief Financial Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112225000521/0001731122-25-000521-index.htm
- Executive change
  Esha Randhawa resigned as member of the Board of Directors at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: member of the Board of Directors
  source text: On April 2, 2025, Esha Randhawa, Charn Deol, and Judy Su each resigned from their positions as members of the Board of Directors of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112225000521/0001731122-25-000521-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.